Abstract: Catalysis has become an indispensable, frequently applied tool for devising convergent, innovative, asymmetric and economical synthesis of APIs in the pharmaceutical industry. BI-Catalysis group, established in Ridgefield in 2008, contributed to the development of novel processes in many BI projects at all stages of research and development through close collaboration with all BI sites. In addition to the screening function of commercially available ligands, an innovative family of tunable BI-ligands was developed and emerged as privileged
ligands for applications to asymmetric catalysis. Screening capacity of catalytic reactions and selected examples from BI projects will be presented.